Arrays Come of Age

Premium

Just a couple of years ago, you couldn’t pass through a crowded hallway at an array conference without hearing that dreaded word: reproducibility. Now, it seems that arrays are finally coming into their own — according to a GenomeWeb survey sent out to microarray users in February, fewer than a third of respondents thought reproducibility was much of a problem. Cost, though, remains prohibitive, according to our survey data. Below are some of the highlights of our microarray snapshot.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.